Elevance Health, Inc. (ELV) Factsheet
Elevance Health, Inc. (ELV) Stock Analysis
Analysis from 10-Q filed 2025-10-21. Data as of Q1 2026.
Overall Grade: F (Concerning)
Grade F (Concerning). ROIC N/A. FCF margin 3.2%. D/E 0.7x. Source: 10-Q filed 2025-10-21.
| Metric | Value | Context |
|---|---|---|
| ROIC | N/A | Below expectations |
| FCF Margin | 3.2% | Cash flow pressure |
| Debt/Equity | 0.7x | Moderate leverage |
FCF margin 3.2% — Bottom 50%.
Explore Elevance Health, Inc.: Earnings History | Filings | ROIC Analysis
Programmatic access: Available via MCP at mcp.metricduck.com. Tools for ELV: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.
Profitability: Elevance Health, Inc. earns N/A ROIC
ROIC TTM N/A, sector median 20.8%. Source: 10-Q filed 2025-10-21.
| Metric | ELV | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | N/A | Red flag | Below sector median of 20.8% |
| Return on Equity (ROE) | 12.0% | Adequate | Moderate equity returns |
Cash Flow: Elevance Health, Inc. generates $6.5B FCF at 3.2% margin, positive NaN/8 quarters
FCF TTM $6.5B. FCF margin 3.2%, Bottom 50%. OCF/Net income 1.5x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-10-21.
| Metric | ELV | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 3.2% | Warning | Thin cash margins |
| Free Cash Flow (TTM) | $6.5B | Good | Positive cash generation |
| OCF/Net Income | 1.5x | Excellent | High earnings quality |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: Elevance Health, Inc. at 0.7x leverage
Debt/Equity 0.7x. Net cash $3.7B. Source: 10-Q filed 2025-10-21.
| Metric | ELV | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.7x | Adequate | Moderate leverage |
| Net Cash Position | $3.7B | Excellent | Net cash positive |
Valuation: Elevance Health, Inc. trades at 12.1x earnings
P/E 12.1x. EV/Sales 0.3x. FCF yield 10.2%. Dividend yield 2.4%. Source: 10-Q filed 2025-10-21.
| Metric | ELV | Rating | Context |
|---|---|---|---|
| P/E Ratio | 12.1x | Adequate | Reasonable valuation |
| EV/Sales | 0.3x | Excellent | Attractive revenue multiple |
| FCF Yield | 10.2% | Excellent | Attractive cash return |
| Dividend Yield | 2.4% | Adequate | Growth focus over income |
Capital Allocation: Elevance Health, Inc. returns 6.9% shareholder yield
Total shareholder yield 6.9% (div 2.4% + buyback 4.5%). Capital returned $4.4B TTM. Source: 10-Q filed 2025-10-21.
| Metric | ELV | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 6.9% | Excellent | Dividend + buyback yield combined |
| Buyback Yield | 4.5% | Good | Active share repurchases |
| Total Capital Returned (TTM) | $4.4B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Free Cash Flow Margin | 3.2% | Bottom 50% | 0.2x below |
| Return on Equity (ROE) | 12.0% | Top 50% | 1.1x above |
| P/E Ratio | 12.1x | N/A | - |
Financial Scorecard
| Metric | ELV | Rating | Sector Context |
|---|---|---|---|
| Free Cash Flow Margin | 3.2% | Warning | Bottom 50% of sector (median: 20.9%) |
| Debt to Equity Ratio | 72.5% | Adequate | Elevated but manageable |
| P/E Ratio (Price-to-Earnings) | 12.1x | Adequate | Attractively valued |
| Free Cash Flow Yield | 10.2% | Excellent | High cash return |
Frequently Asked Questions
Q: What is Elevance Health, Inc.'s Return on Invested Capital (ROIC)?
Elevance Health, Inc. (ELV) has a trailing twelve-month Return on Invested Capital (ROIC) of N/A. Sector median 20.8%. Source: 10-Q filed 2025-10-21.
Q: What is Elevance Health, Inc.'s Free Cash Flow Margin?
Elevance Health, Inc. (ELV) has a free cash flow margin of 3.2%, generating $6.5 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-10-21.
Q: What is Elevance Health, Inc.'s P/E ratio and how does it compare to peers?
Elevance Health, Inc. (ELV) trades at a P/E ratio of 12.1x, which is above the sector median of N/A. EV/Sales 0.3x. FCF yield 10.2%. Source: 10-Q filed 2025-10-21.
Q: Does Elevance Health, Inc. pay a dividend?
Elevance Health, Inc. (ELV) currently pays a dividend yield of 2.4%. Total shareholder yield (dividend + buybacks) 6.9%. Source: 10-Q filed 2025-10-21.
Q: How much debt does Elevance Health, Inc. have?
Elevance Health, Inc. (ELV) has a debt-to-equity ratio of 0.7x with total debt of $31.8 billion. Net cash position $3.7 billion. Source: 10-Q filed 2025-10-21.
Q: What is Elevance Health, Inc.'s revenue and earnings growth?
Elevance Health, Inc. (ELV) grew revenue by 9.3% year-over-year. EPS -8.1% YoY. Source: 10-Q filed 2025-10-21.
Q: Is Elevance Health, Inc. buying back stock?
Elevance Health, Inc. (ELV) repurchased $2.8 billion of stock over the trailing twelve months. This represents a buyback yield of 4.5%. Source: 10-Q filed 2025-10-21.
Q: How does Elevance Health, Inc. compare to competitors in Financials?
Compared to other companies in Financials, Elevance Health, Inc. (ELV) shows: ROIC N/A, sector median 20.8% (NaNx). FCF margin 3.2%, sector median 20.9% (Bottom 50%). These rankings are based on MetricDuck's analysis of all Financials companies with available SEC filings.
Q: What warning signs should I watch for with Elevance Health, Inc.?
Quantitative warning flags for Elevance Health, Inc. (ELV): 1) FCF margin 3.2% (below 5%). Source: 10-Q filed 2025-10-21.
Data Source: Data sourced from 10-Q filed 2025-10-21. TTM metrics as of Q1 2026.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.